F15845 HBr | CAS#866760-23-8

MedKoo Cat#: 556140 | Name: F15845 HBr

Description:

WARNING: This product is for research use only, not for human or veterinary use.

F 15845 is a blocker of the persistent sodium current prevents consequences of hypoxia in rat femoral artery. F15845 has been shown to selectively inhibit the persistent sodium current of Nav1.5[1] exerting cardioprotective effects following ischemia. In vitro testing showed minimal effects of F15845 on other important ion channels of the heart, including major Ca2+ and K+ channels.[1] This characteristic is thought to account for the limited effect of F15845 to change other heart parameters such as basal cardiac function, hemodynamic functions and ventricular fibrillation. F15845 was also shown to exert improved effects when the membrane potential was depolarized,[1] by acting on the extracellular side of the channel.

Chemical Structure

F15845 HBr

CAS#866760-23-8 (HBr)

Theoretical Analysis

MedKoo Cat#: 556140

Name: F15845 HBr

CAS#: 866760-23-8 (HBr)

Chemical Formula: C20H26BrNO2S2

Exact Mass:

Molecular Weight: 456.46

Elemental Analysis: C, 52.63; H, 5.74; Br, 17.51; N, 3.07; O, 7.01; S, 14.05

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

470454-73-0 (free base) 866760-23-8 (HBr) 470454-74-1 (fumarate)

Synonym

F15845 HBr; F15845 hydrobromide; F15845; F-15845; F 15845;

IUPAC/Chemical Name

(S)-N-((S)-3-((2-methoxyphenyl)thio)-2-methylpropyl)-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-3-amine hydrobromide

InChi Key

CUWFVJMNULNBTG-MOGJOVFKSA-N

InChi Code

InChI=1S/C20H25NO2S2.BrH/c1-15(13-24-19-9-5-3-7-17(19)22-2)11-21-16-12-23-18-8-4-6-10-20(18)25-14-16;/h3-10,15-16,21H,11-14H2,1-2H3;1H/t15-,16-;/m0./s1

SMILES Code

C[C@H](CSC1=CC=CC=C1OC)CN[C@H]2COC3=CC=CC=C3SC2.[H]Br

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 456.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Antzelevitch C, Nesterenko V, Shryock JC, Rajamani S, Song Y, Belardinelli L. The role of late I Na in development of cardiac arrhythmias. Handb Exp Pharmacol. 2014;221:137-68. doi: 10.1007/978-3-642-41588-3_7. PMID: 24737235; PMCID: PMC4076160. 2: Bocquet A, Sablayrolles S, Vacher B, Le Grand B. F 15845, a new blocker of the persistent sodium current prevents consequences of hypoxia in rat femoral artery. Br J Pharmacol. 2010 Sep;161(2):405-15. doi: 10.1111/j.1476-5381.2010.00912.x. PMID: 20735424; PMCID: PMC2989591. 3: Pignier C, Rougier JS, Vié B, Culié C, Verscheure Y, Vacher B, Abriel H, Le Grand B. Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. Br J Pharmacol. 2010 Sep;161(1):79-91. doi: 10.1111/j.1476-5381.2010.00884.x. PMID: 20718741; PMCID: PMC2962818. 4: Létienne R, Bel L, Bessac AM, Vacher B, Le Grand B. Myocardial protection by F 15845, a persistent sodium current blocker, in an ischemia-reperfusion model in the pig. Eur J Pharmacol. 2009 Dec 10;624(1-3):16-22. doi: 10.1016/j.ejphar.2009.09.032. Epub 2009 Sep 22. PMID: 19778535. 5: Vié B, Sablayrolles S, Létienne R, Vacher B, Darmellah A, Bernard M, Feuvray D, Le Grand B. 3-(R)-[3-(2-methoxyphenylthio-2-(S)-methylpropyl]amino-3,4-dihydr o-2H-1,5-benzoxathiepine bromhydrate (F 15845) prevents ischemia-induced heart remodeling by reduction of the intracellular Na+ overload. J Pharmacol Exp Ther. 2009 Sep;330(3):696-703. doi: 10.1124/jpet.109.153122. Epub 2009 Jun 10. PMID: 19515969. 6: Vacher B, Pignier C, Létienne R, Verscheure Y, Le Grand B. F 15845 inhibits persistent sodium current in the heart and prevents angina in animal models. Br J Pharmacol. 2009 Jan;156(2):214-25. doi: 10.1111/j.1476-5381.2008.00062.x. Epub 2009 Jan 7. PMID: 19133985; PMCID: PMC2697839. 7: Saint DA. Persistent (current) in the face of adversity ... a new class of cardiac anti-ischaemic compounds on the horizon? Br J Pharmacol. 2009 Jan;156(2):211-3. doi: 10.1111/j.1476-5381.2008.00077.x. Epub 2009 Jan 7. PMID: 19133984; PMCID: PMC2697828.